UBS Group’s LianBio American Depositary Shares LIAN Stock Holding History

UBS Group’s Portfolio LIAN Stock Details LIAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-4,399	Closed	-$19.7K	–	10311
2023 Q4	$19.7K	Buy	+4,399	New	+$15.1K	﹤0.01%	7114
2023 Q3	–	Sell	-100	Closed	-$228	–	10179
2023 Q2	$228	Buy	+100	New	+$230	﹤0.01%	8366
2023 Q1	–	Sell	-4,024	Closed	-$6.6K	–	10851
2022 Q4	$6.6K	Buy	4,024 +2,777	+223%	+$4.33K	﹤0.01%	9012
2022 Q3	$2K	Buy	+1,247	New	+$2.98K	﹤0.01%	9827
2022 Q2	–	Sell	-33,491	Closed	-$124K	–	11230
2022 Q1	$124K	Buy	+33,491	New	+$138K	﹤0.01%	5741

Other funds holding LIAN

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

UBS Group's LIAN Position: Q1 2024 in Review

UBS Group sold out of LianBio American Depositary Shares (LIAN) in Q1 2024, closing a stake of 4,399 shares — an estimated $19.7K sold.

UBS Group first reported a position in LIAN in Q1 2022 and held it in 5 quarters. The position peaked at $124K in Q1 2022. 3 funds tracked by Wall St. Rank hold LIAN as of Q1 2024.

UBS Group reported no remaining LianBio American Depositary Shares position as of Q1 2024 after selling out during the quarter.
UBS Group sold 4,399 LianBio American Depositary Shares shares in Q1 2024, an estimated $19.7K.
UBS Group first reported a position in LianBio American Depositary Shares in Q1 2022 and held it in 5 quarters.
UBS Group's LianBio American Depositary Shares position peaked at $124K in Q1 2022.
3 funds tracked by Wall St. Rank held LianBio American Depositary Shares as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.